OREANDA-NEWS. December 14, 2015. ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that further to the December 2015 quarterly FTSE ICB classification changes, ANGLE is being reclassified to Healthcare, sub-sector Biotechnology, effective from Monday 21 December 2015.

ANGLE's proprietary cell separation technology Parsortix is developing a leading position in the fast emerging medical market for liquid biopsy (disease analysis based on a simple blood draw).  Leading cancer centres have demonstrated the performance of ANGLE's Parsortix system in ovarian, breast, prostate and lung cancers.  The liquid biopsy market is projected to be worth US\\$14 billion in the United States alone by 2025 (source: The Goldman Sachs Group, Inc. Global Investment Research "Liquid Biopsy: Could a simple blood test revolutionize cancer care?" dated 6 October 2015).

ANGLE considers that the classification under Healthcare more accurately reflects the existing and future business activities of the Company following its refocus as a pure play specialist medtech company. 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are pleased that the reclassification has been approved. The change in classification will help ensure that peer-group comparisons are meaningful and should also help attract interest from analysts and investors who specifically follow the Healthcare sector."